Maurie Markman, M.D.

When I began my medical oncology career more than 30 years ago, I was determined to be among the first generation of researchers to cure cancer.

Patients with ovarian cancer are living longer than ever.

The field of ovarian cancer is changing rapidly, and moving toward an era of precision medicine.

It is now well recognized that the presence of a molecular abnormality shown to be actionable in one tumor type may be highly clinically relevant in other malignancies.